GlobeNewswire

Datameer 6.3 Drives Data Democratization by Making Data Lakes Actionable

Dela

New productivity and governance features speed time to data lake insights and strengthen data security

SAN FRANCISCO, July 26, 2017 (GLOBE NEWSWIRE) -- Further demonstrating its commitment to creating and enabling data-driven organizations, Datameer today unveiled Datameer 6.3, which makes it easier than ever to create and curate enterprise-grade data lakes and democratize data access for downstream analysis. New features in Datameer 6.3 significantly increase data analyst productivity, deepen connectivity into the Business Intelligence ecosystem, and strengthen security and governancefunctionality, allowing any analyst better access to business-ready information curated directly from the data lake using Datameer.

Driving Adoption of Data Lakes by Streamlining Access to Data

According to a recent McKinsey Global Survey on the organizational use of data and analytics programs, "At high-performing organizations, respondents report much more advanced data and analytics capabilities than their peers," with "data that [is] accessible across [the] organization" being the determining factor most frequently cited by executives at the highest performing companies.

New productivity features introduced in Datameer 6.3 make data engineers and data analysts up to 40 percent more productive. New analytic functions, workbook operations and improved big data sampling for interactive preparation design enhance self-service analyst access to data lakes.

Datameer 6.3 also introduces new and improved BI integration features, like native support for Tableau, export to Tableau in TDE format (complimenting existing export to TDSX format), and a new export connector for Microsoft PowerBI that bolsters previous Integration Link connectivity. These tight integrations empower business analysts to get more mileage out of existing BI investments and more easily extract the answers they need from their data.

"Business analysts simply want easy access to data they can trust," said Todd Talkington, Director of Technology Partnerships at Tableau. "With deeper native Tableau integration, joint Datameer and Tableau customers will enjoy unencumbered productivity and flexibility knowing their analyses are built on trusted big data pipelines that were engineered to feed into their existing workflows."

Extended Hive integration with new support for custom Hive queries and Hive Views in Datameer 6.3 enables both easier ingestion from Hive, and easier export to Hive for consumption by other tools. Additionally, enhanced enterprise security through deeper integration with Active Directory and Secure Impersonation on Hadoop, provides some of the largest bankstelcos and retailers in the world with the comprehensive security needed to fit into their IT infrastructure and deploy into production with confidence.

"As business appetite for data increases, organizations are under pressure to create agile data pipelines to keep up with demand," said Wayne Eckerson, Founder and Principal Consultant at Eckerson Group. "Datameer's self-service and integration capabilities empower a new generation of data engineers to accelerate the delivery of tailored data sets to downstream analysts."

Learn More

To learn more about how Datameer is making it easier than ever to create and curate enterprise-grade data lakes and democratize data access for downstream analysis, register here  to watch on demand, or join the live webinar with Wayne Eckerson, "Optimize Your Information Supply Chain to Deliver Insight" today, July 26, at 11a.m. PT | 2p.m. ET.

About Datameer 

Datameer is the only big data engineering platform that enables the creation, preparation and consumption of an enterprise data lake in a single solution. Datameer helps enterprises gain value from their data lakes in days, not weeks, by empowering data engineers to create secure data pipelines to feed downstream analytic use cases within Datameer, or, in existing BI tooling. Leading brands such as Aetna, American Airlines, British Telecom, National Instruments, Priceline, Sophos and Telefonica all use Datameer to build trusted big data pipelines to feed business-critical analyses. Learn more at www.datameer.com

Connect with Datameer

Subscribe to our company BLOG
Follow us on Twitter
Connect with us on LinkedInGoogle+ and Facebook

Contact
Erin Hitchcock
Datameer, Inc.
PR Manager
erin.hitchcock@datameer.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Datameer via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum